|
gptkbp:instance_of
|
gptkb:vaccine
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:STS-39_patch
|
|
gptkbp:accessories
|
raw material shortages
manufacturing issues
distribution delays
|
|
gptkbp:activities
|
m RNA technology
|
|
gptkbp:approves
|
gptkb:2021
|
|
gptkbp:average_temperature
|
-20° C
|
|
gptkbp:clinical_trial
|
gptkb:Europe
gptkb:Asia
gptkb:North_America
30,000
Phase 3
|
|
gptkbp:developed_by
|
gptkb:XYZ_Pharmaceuticals
|
|
gptkbp:distribution
|
gptkb:initiative
bilateral agreements
donations to low-income countries
|
|
gptkbp:dosage_form
|
two doses
recommended after 6 months
|
|
gptkbp:effective_date
|
emergency use authorization
|
|
gptkbp:future_plans
|
long-term immunity
combination vaccines
variant effectiveness
|
|
gptkbp:healthcare
|
reduces transmission
contributes to herd immunity
prevents hospitalization
reduces severity of disease
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
SPLAT-19
|
|
gptkbp:is_effective_against
|
95%
|
|
gptkbp:is_tested_for
|
clinical trials
|
|
gptkbp:is_vulnerable_to
|
gptkb:vaccine
|
|
gptkbp:manager
|
intramuscular injection
|
|
gptkbp:manufacturer
|
gptkb:XYZ_Pharmaceuticals
|
|
gptkbp:market
|
ongoing
|
|
gptkbp:production_location
|
gptkb:Australia
gptkb:UK
gptkb:USA
gptkb:Native_American_tribe
|
|
gptkbp:public_perception
|
generally positive
vaccine hesitancy
|
|
gptkbp:receives_funding_from
|
government grants
private investments
philanthropic donations
|
|
gptkbp:side_effect
|
fatigue
headache
muscle pain
fever
thrombosis
anaphylaxis
pericarditis
myocarditis
|
|
gptkbp:targets
|
gptkb:COVID-19
|